TY - JOUR
T1 - Effects of the GABAergic drug, sodium valproate, on the prolactin release evoked by pharmacological stimuli in normal women
AU - Melis, G. B.
AU - Fruzzetti, F.
AU - Paoletti, A. M.
AU - Mais, V.
AU - Beneventi, F.
AU - Trimarchi, G.
AU - Fioretti, P.
PY - 1984
Y1 - 1984
N2 - Sodium valproate (DPA or Na-dipropylacetate), an anticonvulsant drug activating the endogenous GABAergic system, was administered orally at the dose of 400 mg to seventeen normal women 1 h before intravenous injections with three drugs which stimulate prolactin (PRL) release: TRH (200 μg bolus; six subjects); domperidone (5 mg bolus; six subjects); and sulpiride (5 mg bolus; five subjects). DPA pretreatment significantly blunted PRL response to both domperidone and sulpiride injections without affecting the PRL response to TRH. In particular, the quantitative PRL secretion (areas under curves) following domperidine and sulpiride tests appeared significantly reduced after DPA treatment in comparison to placebo (P <0.02 and P <0.01 for domperidine and sulpiride respectively). These results indicate that the pharmacological enhancement of the endogenous GABAergic system by DPA may blunt PRL response to both central and peripheral dopamine receptor blockade. These observations suggest that a GABAergic pathway inhibiting PRL secretion at the hypothalamic level competes, at least in part, with the dopaminergic system. Conversely, the lack of any effect of DPA on PRL response to TRH seems to suggest that pituitary TRH receptors are independent of any GABAergic control.
AB - Sodium valproate (DPA or Na-dipropylacetate), an anticonvulsant drug activating the endogenous GABAergic system, was administered orally at the dose of 400 mg to seventeen normal women 1 h before intravenous injections with three drugs which stimulate prolactin (PRL) release: TRH (200 μg bolus; six subjects); domperidone (5 mg bolus; six subjects); and sulpiride (5 mg bolus; five subjects). DPA pretreatment significantly blunted PRL response to both domperidone and sulpiride injections without affecting the PRL response to TRH. In particular, the quantitative PRL secretion (areas under curves) following domperidine and sulpiride tests appeared significantly reduced after DPA treatment in comparison to placebo (P <0.02 and P <0.01 for domperidine and sulpiride respectively). These results indicate that the pharmacological enhancement of the endogenous GABAergic system by DPA may blunt PRL response to both central and peripheral dopamine receptor blockade. These observations suggest that a GABAergic pathway inhibiting PRL secretion at the hypothalamic level competes, at least in part, with the dopaminergic system. Conversely, the lack of any effect of DPA on PRL response to TRH seems to suggest that pituitary TRH receptors are independent of any GABAergic control.
UR - http://www.scopus.com/inward/record.url?scp=0021350820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021350820&partnerID=8YFLogxK
M3 - Article
C2 - 6426828
AN - SCOPUS:0021350820
SN - 0300-0664
VL - 20
SP - 245
EP - 252
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 3
ER -